KFS
IONS icon

Kurt F. Somerville’s Ionis Pharmaceuticals IONS Stock Holding History

Kurt F. Somerville’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-5,079
Closed -$258K – 106
2017
Q2 		$258K Sell
5,079
-12,052
-70% -$561K 0.05% 93
2017
Q1 		$689K Sell
17,131
-10,650
-38% -$478K 0.15% 66
2016
Q4 		$1.33M Sell
27,781
-1,960
-7% -$77.6K 0.29% 51
2016
Q3 		$1.09M Sell
29,741
-1,335
-4% -$41.8K 0.24% 58
2016
Q2 		$722K Buy
31,076
+1,600
+5% +$51.6K 0.16% 68
2016
Q1 		$1.19M Buy
29,476
+750
+3% +$30.5K 0.27% 56
2015
Q4 		$1.78M Sell
28,726
-76
-0.3% -$4.1K 0.41% 51
2015
Q3 		$1.16M Sell
28,802
-105
-0.4% -$5.43K 0.3% 54
2015
Q2 		$1.66M Buy
28,907
+145
+0.5% +$9.22K 0.38% 49
2015
Q1 		$1.83M Buy
28,762
+4,100
+17% +$278K 0.42% 47
2014
Q4 		$1.52M Buy
24,662
+14,557
+144% +$718K 0.38% 53
2014
Q3 		$393K Buy
10,105
+145
+1% +$5.14K 0.16% 80
2014
Q2 		$342K Buy
+9,960
New +$314K 0.13% 85

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Kurt F. Somerville's IONS Position: Q3 2017 in Review

Kurt F. Somerville sold out of Ionis Pharmaceuticals (IONS) in Q3 2017, closing a stake of 5,079 shares — an estimated $258K sold.

Kurt F. Somerville first reported a position in IONS in Q2 2014 and held it in 13 quarters. The position peaked at $1.83M in Q1 2015. 301 funds tracked by Wall St. Rank hold IONS as of Q3 2017.

  • Kurt F. Somerville reported no remaining Ionis Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Kurt F. Somerville sold 5,079 Ionis Pharmaceuticals shares in Q3 2017, an estimated $258K.
  • Kurt F. Somerville first reported a position in Ionis Pharmaceuticals in Q2 2014 and held it in 13 quarters.
  • Kurt F. Somerville's Ionis Pharmaceuticals position peaked at $1.83M in Q1 2015.
  • 301 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2017.

Based on Kurt F. Somerville's 13F filing for Q3 2017, filed 26 Oct 2017.